A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set
Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.
Put together by software, not yet checked by a person
Why this status
2 Feb 2024: Trial registered, NCT06239272
27 Mar 2024: Trial started, NCT06239272
The trials
NCT06239272: NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
State
Under way
Phase
Phase 1 and Phase 2
People
139 planned
Started
27 Mar 2024
Primary completion
Jun 2034
Arms
Intermediate-Risk Subset A (participants with low grade tumors):, Intermediate-Risk Subset B (participants with high-grade tumors between 5 and 10 cm in size, Intermediate-Risk Subset C (participants with high-grade tumors > 10 cm):
Results
None posted
2 Feb 2024: Trial registered
27 Mar 2024: Trial started
How the status changed
19 Nov 2026: First set: Phase 1 trial
Registries searched: ClinicalTrials.gov, through 17 Nov 2026.